Background: HIV–associated Lipodystrophy (HAL) is a syndrome that occurs in HIV–infected patients who are being treated with antiretroviral drugs. Lipodystrophy is cosmetically disfiguring. Involvement of the face is most common and carries a social stigma, reducing the quality of life of patients with HIV disease. It also imposes a barrier to treatment and decrease adherence to ART medicines. These patients with are at increased risk for the development of diabetes mellitus and atherosclerosis. Aim of the study: To compare the prevalence of Diabetes Melitus in HAART (highly active anti retroviral therapy) patients with HIV–associated Lipodystrophy and without HIV–associated Lipodystrophy. Materials and Methods: After getting the patients consent, 52 HAART patients with Lipodystrophy were enrolled in group A and 62 HAART patients without Lipodystrophy were enrolled in group B. Blood samples for fasting and post–prandial blood glucose were taken from both the groups. Results: In group A, among the 52 patients enrolled, 15 were male (29%) and 37 female (71%). Predominant age group involved was 20–30 years. Patients on ZLN regimen were 37 (71%), TLE 12(23%) and ZLE 3(6%). Out of these, 7 (13.5%) patients had Diabetes Melitus. In group B, among the 62 patients enrolled, 31 were male (50%) and 31 female (50%). Predominant age group involved was 20–30 years. Patients on ZLN regimen were 44 (71%), TLE 13(21%), ZLE 4(6%) and TLN 1 (2%). Out of these, 11 (17.7%) patients had Diabetes Melitus. Chi–Square test was employed to find out the stastical difference of diabetic prevalence, but there was no such difference. Conclusion: This study has revealed that association of HIV associated Lipodystrophy does not influence the prevalence of Diabetes Melitus in HIV patients.